All News

PsA.Xray_.Erosion.Cup_.jpg

Guselkumab gets FDA Nod for X-ray Protection

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
SI AS SpA ACR

Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis

Jack Cush, MD

Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and

Read Article
LBP_0.jpg

Chronic Low Back Pain Disappointments in a Randomized Trial

Jack Cush, MD

Annals of Internal Medicine reports that patients with chronic low back pain (cLBP) may benefit from physical therapy (PT); but when that fails, other secondary measures (cognitive behavioral therapy (CBT) or mindfulness) may not be effective.

Read Article
RheumNow Podcast square

Influential Rheumatoid Factors (5.8.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Read Article
RheumNow Podcast square

Follow the Money (4.23.2026)

Jack Cush, MD

Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week. 

Read Article
RheumNow Podcast square

Prescribing Lessons (4.17.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
🔍 What defines a positive MRI for #axSpA? SPARTAN-SSR consensus (n=1,050): BME≥3 slices or 2/3 lesions in ≥3 SIJ quadrants #OP0100 #EULAR2026 @RheumNow https://t.co/nfhzGxBZOm

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Interesting pilot study using line-field confocal OCT for CLE The “virtual biopsy” identified distinct layer-specific patterns across diff CLE subtypes including distinctions bet ACLE & rosacea (dil. vessels, demodex mites, periannexal infil) AbsOP099 @RheumNow #EULAR2026 https://t.co/yQSc6u4oYV

Links:

sheila RHEUMarampa ( View Tweet)
Psoriatic arthritis #PsA sessions raised important topics on intercepting arthritis in psoriasis, treating obesity as a disease target, synovial biopsy to guide treatment, molecular imaging to reveal subclinical disease. More tomorrow. #Rheumatology @RheumNow #EULAR2026

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Multiparametric renal MRI in LN: Structural MRI can differentiate bet. active and stable dse Exudative = active inflamm In quanti analysis, low ADC values may reflect fibrosis. A potential non-invasive biomarker? OP092 @rheumNow #EULAR2026 https://t.co/IarTGOen7v

Links:

sheila RHEUMarampa ( View Tweet)
This retrospective cohort of NPSLE pts showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI Pts w/ diffuse symptoms - normal MRI except brain atrophy Interesting to know how this can aid in future mgt strategies for NPSLE OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK

Links:

sheila RHEUMarampa ( View Tweet)
68Ga-RGD PET/CT in PsA reveals large chunk of “silent” synovitis 15 pts 1020 joints 35% affected joints clinically silent PET signal correlation w/ disease burden: DAPSA (ρ=0.66) CRP (ρ=0.69) Pilot study — not confirmed with US Needs validation but intriguing signal #OP068 https://t.co/nhS7PDZN0A

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Abst# OP068: 68Ga-RGD PET/CT imaging detected subclinical synovitis in 35% of joints that were clinically silent in #PsA. Molecular imaging may reveal the true burden of joint disease before it declares clinically. @RheumNow #EULAR2026 #PsoriaticArthritis

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

You CAN identify #ILD in #rheumatic #diseases 🔜early With a brief #questionnaire Ask re ➡️dry cough ➡️dyspnea ➡️smoking Not sensitive but high #specificity Is it too late? Maybe chest #auscultation at the #bases would be better? 🤷 #EULAR2026 ABST#POS0433 @RheumNow https://t.co/JA3k1cSHt7

Links:

Janet Pope Janetbirdope ( View Tweet)
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/k7tVeJFeCi
Dr. John Cush RheumNow ( View Tweet)
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/jtHgVABFiA
Dr. John Cush RheumNow ( View Tweet)
Study of 305 newly Dx axSpA pts (age 38 yrs; 55% male, Dx delay 6yrs, 75% B27+). Clinical Dx, without Xray/imaging in 12%, 5% developed sacroiliitis during 8 yr F/U. r-axSpA mostly male w/ ^CRP https://t.co/zWJDRdBSWC https://t.co/nWFnEgp5Zf

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 305 newly Dx axSpA pts (age 38 yrs; 55% male, Dx delay 6yrs, 75% B27+). Clinical Dx, without Xray/imaging in 12%, 5% developed sacroiliitis during 8 yr F/U. r-axSpA mostly male w/ ^CRP https://t.co/zGjb3uSkjP https://t.co/3bdGAvKXAm

Links:

Dr. John Cush RheumNow ( View Tweet)
A Review of Hydroxychloroquine Ocular Toxicity While HCQ is thought to be a very safe drug, its ocular risk profile is probably more serious than appreciated. A comprehensive review published in the Journal of Rheumatology discusses HCQ pharmacokinetics, mechanisms of retinal https://t.co/BrENoaBAVx
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×